These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36233472)

  • 1. The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
    Liposits G; Skuladottir H; Ryg J; Winther SB; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.
    Liposits G; Ryg J; Skuladottir H; Winther SB; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
    J Geriatr Oncol; 2023 Jan; 14(1):101408. PubMed ID: 36494261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
    Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
    PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
    Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
    Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
    Liposits G; Eshøj HR; Möller S; Winther SB; Skuladottir H; Ryg J; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Österlund P; Glimelius B; Sorbye H; Pfeiffer P
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
    van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
    Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
    PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy.
    Guo G; Chen X; Cai X; Chen Y; Wang H; Fan L; Bai L; Qiu H; Zhang B
    Transl Cancer Res; 2019 Aug; 8(4):1137-1147. PubMed ID: 35116856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
    Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities.
    Sørensen MS; Colding-Rasmussen T; Horstmann PF; Hindsø K; Dehlendorff C; Johansen JS; Petersen MM
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer.
    Videmark AN; Christensen IJ; Feltoft CL; Villadsen M; Borg FH; Jørgensen BM; Bojesen SE; Kistorp C; Ugleholdt R; Johansen JS
    Cancer Med; 2023 Mar; 12(6):6675-6688. PubMed ID: 36440611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
    Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.
    Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
    Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade.
    Li S; Zou J; Liu C; Jiao X; Gong J; Li J; Wang Z; Lu M; Lu Z; Shen L
    Clin Immunol; 2020 Mar; 212():108345. PubMed ID: 31953149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.